Can-Fite BioPharma (CANF) Accumulated Expenses (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Accumulated Expenses came in at $1.1 million in Q4 2025, up 13.63% YoY from $976000.0 in Q4 2024, and up 119.17% on a QoQ basis from $506000.0 in Q2 2025.
Can-Fite BioPharma (CANF) Accumulated Expenses (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Accumulated Expenses data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Accumulated Expenses rose 13.63% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 13.63% YoY) and the FY2025 annual result came in at $1.1 million, up 13.63% from the prior year.
- Accumulated Expenses climbed to $1.1 million in Q4 2025, from $506000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.1 million in Q4 2025 to a low of $305000.0 in Q3 2021.
- A 5-year average of $703687.5 and a median of $736000.0 in 2021 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 173.41% in 2021, down 34.53% in 2021.
- Tracing CANF's Accumulated Expenses over 5 years: stood at $905000.0 in 2021, then retreated by 14.36% to $775000.0 in 2022, then advanced by 21.81% to $944000.0 in 2023, then rose by 3.39% to $976000.0 in 2024, then climbed by 13.63% to $1.1 million in 2025.
- The last three Accumulated Expenses figures came in at $1.1 million (Q4 2025), $506000.0 (Q2 2025), and $976000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.11 Mn |
| Jun 30, 2025 | 506,000.00 |
| Dec 31, 2024 | 976,000.00 |
| Jun 30, 2024 | 430,000.00 |
| Dec 31, 2023 | 944,000.00 |
| Sep 30, 2023 | 746,000.00 |
| Jun 30, 2023 | 596,000.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 775,000.00 |
| Sep 30, 2022 | 458,000.00 |
| Jun 30, 2022 | 464,000.00 |
| Mar 31, 2022 | 907,000.00 |
| Dec 31, 2021 | 905,000.00 |
| Sep 30, 2021 | 305,000.00 |
| Jun 30, 2021 | 309,000.00 |
| Mar 31, 2021 | 726,000.00 |
| Dec 31, 2020 | 331,000.00 |
| Jun 30, 2020 | 472,000.00 |
| Dec 31, 2019 | 610,000.00 |
| Sep 30, 2019 | 351,000.00 |